Recently, the National Pharmaceutical Industry Information Annual Conference 2021 hosted by China National Pharmaceutical Industry Information Center of MIIT was held in Jinan, during which the rankings for 2021, including China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline, were released. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. （"Hansoh Pharma" or the "Company"） has been ranked top three among "China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline" for consecutive years with its long-term leading R&D and innovation capabilities.
Another authoritative affirmation of R&D strength
The "China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline" ranking is one of the most authoritative and representative industry rankings in China, aiming to track R&D dynamics at home and abroad in real time and identify the strongest voice in the domestic pharmaceutical R&D field. As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma has been ranked top three among "China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline" for consecutive years, which is not only an evidence of the Company's strong strength in the field of pharmaceutical innovation, but also another authoritative affirmation of its comprehensive innovation strength.
Strong momentum in innovation and R&D
Since its establishment, Hansoh Pharma has taken innovation and R&D as its core strategy for development. After years of hard work, Hansoh Pharma has made continuous and intensive R&D investment to provide strong support for innovation and development, and has entered the harvest period of R&D achievements. In July alone, the Company has submitted applications for four new Class 1 drugs, all of which have been accepted by CDE. Hansoh Pharma now has five new Class 1 drugs on the market, more than 100 drugs under development, and more than 20 innovative drugs in the clinical stage, including 4 biological drugs, an evidence of its innovative R&D strength.
It is worth mentioning that the Company has established R&D centers in Maryland, the U.S., and Shanghai, Lianyungang，Changzhou of China, focusing on the unmet clinical needs in major disease treatment fields including oncology, CNS, anti-infectives and diabetes, and has built a complete R&D system and innovation platform covering pharmacy, clinical research and registration filing. Hansoh Pharma always adheres to "endogenous" independent R&D, and keeps growing its original innovation capability.
Accelerated internationalization of innovations
While Hansoh Pharma continues to build up its strength in innovation and R&D, BD internationalization has also accelerated to a deeper level. The Company has not only co-founded Blossom Biosciences with Cormorant Asset Management for platform incubation, but also reached strategic cooperation with EQRx.Inc., Viela Bio, Terns Pharmaceuticals, NiKang Therapeutics, Atomwise, etc. to integrate resource advantages by "bringing in" and "going out", so that the in-depth BD internationalization process can be steadily promoted for the benefit of patients worldwide.
Hansoh Pharma always stays "focused, professional and committed", upholds the corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", insists on the focus on patients' benefits, and strives to accelerate diversified innovation, with an aim to meet the unmet medical needs in clinical practice and help promote China's pharmaceutical industry to evolve from a leader in size to a leader in strength.
